BLCO Gains European CE Mark for Next-Gen SeeLyra Femtosecond Laser

Bausch + Lomb BLCO recently announced that its next-generation SeeLyra femtosecond laser has received European CE Mark approval, expanding the company’s surgical portfolio in the European market. The platform is designed to provide precision and control during laser-assisted preparation for premium cataract, LASIK flap and corneal therapeutic surgeries while supporting efficient workflows in modern operating rooms (ORs).

Per management, SeeLyra builds on BLCO’s more than 15 years of experience in the femtocataract laser market and is designed to combine enhanced functionality with greater flexibility in the OR. The platform provides surgeons with precise surgical preparation and controlled conditions for premium cataract procedures while addressing space limitations and workflow efficiency.

BLCO Stock Trend Following the News

BLCO stock has lost 1.7% since the announcement on Friday. Year to date, the stock has gained 1% compared with the industry’s 1.9% growth and the S&P 500’s 11.4% rise.

The European CE Mark strengthens BLCO’s surgical technology portfolio and provides an opportunity to expand its presence in the femtosecond laser market. SeeLyra’s applications across cataract, LASIK and corneal therapeutic procedures could broaden its addressable market, while its compact and mobile design may improve adoption among space-constrained ORs. Regulatory efforts in additional markets, including the United States, could provide further commercial opportunities and support long-term growth in BLCO’s surgical business.

BLCO currently has a market capitalization of $6.16 billion.

Image Source: Zacks Investment Research

More on SeeLyra

SeeLyra incorporates live swept-source OCT, enabling real-time visualization of the eye’s depth during procedures. The technology is designed to support consistent docking, precise positioning of laser cuts and visual control during laser application. The platform also retains features from Bausch + Lomb’s VICTUS femtosecond system, including an intuitive user interface and adaptability across multiple surgical procedures.

The compact design and absence of a fixed patient bed allow SeeLyra to be positioned and transported more flexibly within modern OR environments. Compatibility with existing bed configurations can also help streamline procedures and improve patient comfort by eliminating the need to transfer patients between beds. An articulating swing arm further allows surgeons to select their preferred surgical orientation.

SeeLyra’s European launch is planned initially on a limited basis, with broader availability anticipated in 2027. Bausch + Lomb is also pursuing regulatory approvals in markets worldwide, including the United States, although indications and approvals may vary by country.

Industry Prospects Favoring the Market

According to data provided by Coherent Market Insights, the global ophthalmic femtosecond lasers market is estimated to be $1.28 billion in 2026 and is expected to witness a CAGR of 7.5% through 2033.

Factors such as the growing adoption of precision-based ophthalmic procedures, rising demand for advanced cataract and refractive surgeries, increasing prevalence of vision disorders and continued technological advancements in femtosecond laser systems are expected to support market growth.

Other News

Bausch + Lomb recently announced that two first-in-class pharmaceutical pipeline candidates will advance to the next stages of clinical development following positive trial results. The programs include a dual-action eye drop for dry eye disease that is moving into Phase 3 and BL1332, an investigational treatment for ocular surface pain, which will continue in Phase 2.

Bausch + Lomb Corporation Price

Bausch + Lomb Corporation price | Bausch + Lomb Corporation Quote

BLCO’s Zacks Rank & Key Picks

Currently, BLCO carries a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are Veracyte VCYT, Globus Medical GMED and West Pharmaceutical WST.

Veracyte, currently sporting a Zacks Rank #1 (Strong Buy), reported second-quarter 2026 adjusted earnings per share (EPS) of 54 cents, which surpassed the Zacks Consensus Estimate by 25.6%. Revenues of $150.3 million beat the Zacks Consensus Estimate by 4.1%. You can see the complete list of today’s Zacks #1 Rank stocks here.

VCYT has an estimated earnings growth rate of 8.4% for 2026. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 41.8%.

Globus Medical, currently sporting a Zacks Rank #1, reported second-quarter 2026 adjusted EPS of $1.34, which surpassed the Zacks Consensus Estimate by 19.6%. Revenues of $789.6 million beat the Zacks Consensus Estimate by 0.4%.

GMED has an estimated long-term earnings growth rate of 12.4%. The company’s earnings beat estimates in each of the trailing four quarters, the average surprise being 27.9%.

West Pharmaceutical, carrying a Zacks Rank #2 (Buy) at present, reported second-quarter 2026 adjusted EPS of $2.37, which beat the Zacks Consensus Estimate by 13.9%. Revenues of $872.3 million surpassed the Zacks Consensus Estimate by 4.2%.

WST has an estimated long-term earnings growth rate of 16%. WST’s earnings surpassed estimates in the trailing four quarters, the average surprise being 17.4%.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

Of course, all our elite picks aren't winners, but this one could far surpass earlier Zacks' Stocks Set to Double like D-Wave Quantum, which shot up +680.1%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research